Gemcitabine combined with apatinib and toripalimab in recurrent or metastatic nasopharyngeal carcinoma

Rui You,Xiong Zou,Xi Ding,Wei-Jing Zhang,Meng-Xia Zhang,Xiao Wang,Han-Shi Xu,Yong-Long Liu,Yan-Feng Ouyang,Chong-Yang Duan,Chen-Mei Gu,Zhi-Qiang Wang,You-Ping Liu,Yi-Jun Hua,Pei Yu Huang,Ming-Yuan Chen

Med（2022）

引用 4|浏览7

暂无评分

摘要

•The gemcitabine, apatinib, toripalimab (GAT) therapy is potentially effective in R/M NPC•GAT therapy is generally safe; nasopharynx necrosis is a complication of concern•Risk factors for necrosis are repeated radiotherapy, <12 months from last radiotherapy•High MRGPRF expression in tumors correlates with poor PFS from the GAT therapy

查看译文

关键词

nasopharyngeal carcinoma,apatinib,toripalimab,gemcitabine,recurrent/metastatic,genomic,transcriptional analyses,MRGPRF,ct-DNA sequencing

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要